Last updated: February 22, 2026
What is the Drug with NDC 43598-0704?
NDC 43598-0704 is associated with Praxbind (idarucizumab), a monoclonal antibody used as a specific reversal agent for the anticoagulant dabigatran (Pradaxa). Approved by the FDA in October 2015, Praxbind is indicated for emergency reversal of dabigatran in patients with uncontrolled bleeding or who require urgent surgery or procedures.
Market Size and Adoption
Market Drivers
- Increasing use of dabigatran: Sales of dabigatran (Pradaxa) peaked in 2021, with approximately 14 million prescriptions filled globally (IQVIA, 2022). As dabigatran use expands, the demand for its reversal agent grows.
- Emergency Hemorrhage Management: Hospitals frequently require rapid reversal of anticoagulation, boosting demand for Praxbind.
- Regulatory Approvals: Approved in multiple regions, including the US, EU, and Japan, broadening market access.
Clinical Usage
- Indications: Emergency bleeding reversal, urgent surgeries.
- Prescribing Trends: Approximate annual demand in the US exceeds 100,000 doses, based on hospital utilization rates (MarketScope, 2022).
Market Penetration
- Estimated market penetration rate in hospitals remains around 60–70% due to logistical adoption barriers and competing reversal agents like Andexanet alfa, though the latter is for Factor Xa inhibitors, not dabigatran.
Pricing Analysis
Pricing Benchmarks
- List Price (US): As of 2023, the wholesale acquisition cost (WAC) per 5g dose is approximately $3,800 to $4,300.
- Average Selling Price (ASP): Payor negotiations typically reduce actual transaction prices by 10–20%.
Cost Comparison
| Parameter |
Praxbind (Idarucizumab) |
Competing Reversal Agents |
| Price per dose |
~ $4,000 |
N/A (for Factor Xa inhibitors) |
| Dosing |
5 grams for reversal |
4–8 grams depending on patient weight |
| Administration |
IV infusion |
IV infusion |
Price Trends
- Marginal increases from initial launch prices (~$3,500) due to inflation and manufacturing costs.
- No significant discounts for bulk hospital purchasing contracts recorded publicly.
Reimbursement Landscape
- Reimbursed primarily through Medicare and private insurers.
- Reimbursement rates approximate $4,000–$4,500 per dose, leaving institutions with various profit margins.
Competitive Environment and Market Dynamics
Main Competitors
- Idarucizumab (Praxbind) dominates the specific reversal market for dabigatran.
- Andexanet alfa (Andexxa), approved in 2018 for Factor Xa inhibitors, presents competition for specific reversal in broader anticoagulant reversal markets, but does not impact Praxbind's niche directly.
Future Market Projections
- Compound annual growth rate (CAGR): 6–8% through 2028, driven by increased anticoagulant use.
- Market expansion potential: Extended indications, off-label uses, and increased adoption could add 10–15% to revenue streams.
Patent and Regulatory Outlook
- Praxbind's initial patent expired in 2023, though secondary patents or formulations may extend exclusivity.
- Regulatory pathways for biosimilars are complex; no biosimilars currently approved or anticipated within the next five years.
Price Projection Summary (2023–2028)
| Year |
Estimated Average Price per Dose |
Comments |
| 2023 |
$4,200 |
Current average price. |
| 2024 |
$4,150 |
Slight decrease due to negotiations. |
| 2025 |
$4,100 |
Market stabilization. |
| 2026 |
$4,050 |
Gaining volume discounts. |
| 2027 |
$4,000 |
Competitive pricing pressures. |
| 2028 |
$3,950 |
Possible biosimilar entry or generic competition. |
Key Takeaways
- Praxbind faces steady demand driven by increased dabigatran prescriptions and hospital emergency scenarios.
- Current list prices range around $4,000 per dose; marginal declines are anticipated as competition and negotiations intensify.
- The market is expected to grow at a CAGR of approximately 7% over the next five years.
- Patent expiration may introduce biosimilars beyond 2023, potentially reducing prices further.
- Reimbursement rates persist near current levels, supporting stable profit margins for providers.
FAQs
Q1: Will biosimilars impact Praxbind’s pricing?
A1: Biosimilar competition could emerge beyond 2023, potentially lowering prices by 10–30%.
Q2: Are there off-label uses that could expand demand?
A2: No significant off-label uses are documented; primary demand aligns with dabigatran reversal cases.
Q3: How does Praxbind compare cost-wise to alternative reversal agents?
A3: Praxbind is more specific to dabigatran and generally priced higher than alternatives for other anticoagulants, but its specificity justifies the premium.
Q4: What regional differences influence pricing?
A4: US pricing is higher due to insurance negotiations; European markets often see lower prices due to national tender systems.
Q5: What regulatory developments could influence future pricing?
A5: Biosimilar approvals, new patents, and expanded indications could alter pricing strategies and market competition.
References
[1] IQVIA. (2022). Pharmaceutical Prescription Trends.
[2] MarketScope. (2022). Hospital Reversal Agent Market Analysis.
[3] U.S. Food and Drug Administration (FDA). (2015). Praxbind (idarucizumab) Approval Letter.
